CASI Pharmaceuticals, Inc. (CASIF)
OTCMKTS
· Delayed Price · Currency is USD
0.210
0.00 (0.00%)
At close: Mar 9, 2026
CASI Pharmaceuticals Revenue
CASI Pharmaceuticals had revenue of $3.08M in the quarter ending September 30, 2025, a decrease of -60.54%. This brings the company's revenue in the last twelve months to $26.85M, up 21.72% year-over-year. In the year 2024, CASI Pharmaceuticals had annual revenue of $28.54M, down -15.77%.
Revenue (ttm)
26.85M
Revenue Growth
+21.72%
P/S Ratio
0.16
Revenue / Employee
115.22K
Employees
233
Market Cap
4.32M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.54M | -5.34M | -15.77% |
| Dec 31, 2023 | 33.88M | -9.23M | -21.41% |
| Dec 31, 2022 | 43.11M | 12.94M | 42.89% |
| Dec 31, 2021 | 30.17M | 15.03M | 99.25% |
| Dec 31, 2020 | 15.14M | 11.01M | 266.52% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vislink Technologies | 27.73M |
| Optec International | 15.55K |
| Clean Vision | 248.30K |
| Next Meats Holdings | 1.05M |
| Luminar Technologies | 75.75M |
| Talon International | 45.48M |
| SUIC Worldwide Holdings | 18.48K |
| Enzon Pharmaceuticals | 26.00K |
CASI Pharmaceuticals News
- 12 days ago - CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel - Accesswire
- 7 weeks ago - CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR) - Accesswire
- 2 months ago - CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia - Accesswire
- 2 months ago - CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements - Accesswire
- 3 months ago - CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing - Accesswire
- 3 months ago - CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting - Accesswire
- 3 months ago - CASI Pharmaceuticals Announces Changes in Board Governance - Accesswire
- 4 months ago - CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results - Accesswire